INCHEON, Korea – October 26, 2023 – Samsung Bioepis Co., Ltd. today announced the company has won ‘Company of the Year, Asia-Pacific, and ‘Regulatory Achievement of the Year’ at the Global Generics & Biosimilars (GGB) Awards 2023, marking the company’s third time of honor for its continuous leadership in biosimilars and commitment to innovating access to treatments for patients around the world.

Samsung Bioepis has been recognized for its best practice and ongoing endeavors to expand treatment options for patients including those with rare diseases through biosimilars. Over the past year, the company became the first to receive FDA approvals for both high concentration and low concentration adalimumab biosimilar in August 2022. Building upon the company’s strength, it also obtained marketing authorization for its eculizumab biosimilar in Europe in May 2023. 

This year, the company has also been shortlisted as finalists for ‘Company of the Year,’ ‘Biosimilar Initiative of the Year,’ and ‘Campaign of the Year.’ Previously, Samsung Bioepis won the GGB Awards for ‘Company of the Year, Asia-Pacific’ category in 2022 and ‘Biosimilar Initiative of the Year’ category in 2020. 

Samsung Bioepis has seven biosimilar products approved in Europe and five in the United States, becoming one of the most expansive and rapidly growing global biopharmaceutical companies since its establishment in 2012. 

The ‘Global Generics & Biosimilars Awards’ are presented annually by the international publishing company Citeline (previously Informa). This year, the event was held in Barcelona, Spain on October 25, to celebrate the greatest achievements and innovations across the development, authorization, marketing and distribution of global off-patent pharmaceuticals and to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change.

# # #

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.